Bristol Myers Is Taking Full Advantage of its Celgene Acquisition
Bristol Myers Squibb (NYSE: BMY) got quite a boost in fourth-quarter revenue from the drugs it received through its acquisition of Celgene. Even looking at an apples-to-apples comparison -- as if Bristol owned the assets in the year-ago quarter -- Celgene's drugs are the ones contributing much of the growth.
In this video from Motley Fool Live recorded on Feb. 8, Fool.com contributors Brian Orelli and Keith Speights discuss how the addition of Celgene has helped Bristol Myers Squibb's top and bottom lines.
Source Fool.com
